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BACKGROUND: The purpose of this study was to evaluate the number of ovarian cancer and primary peritoneal cancer (PPC)
progressive disease cases identified via routine follow-up procedures and the corresponding cost throughout a 16-year period at a
single medical institution.
METHODS: Previously undiagnosed epithelial ovarian (n¼241), PPC (n¼23), and concurrent ovarian and uterine (n¼24) cancer
patients were treated and then followed via CA-125, imaging (e.g., CT scan, chest X-ray), physical examination and vaginal cytology.
RESULTS: In the group of 287 patients, there were 151 cases of disease progression. Serial imaging detected the highest number of
progressive disease cases (66 initial and 45 confirmatory diagnoses), but the cost was rather high ($13454 per patient recurrence),
whereas CA-125 testing (74 initial and 20 corroborative diagnoses) was the least expensive ($3924) per recurrent diagnosis.
The total cost of surveillance during the 16-year period was nearly $2400000.
CONCLUSION: Ultimately, serial imaging and the CA-125 assay detected the highest number of ovarian cancer and PCC progressive
disease cases in comparison to physical examination and vaginal cytology, but nevertheless, all of the procedures were conducted at a
considerable financial expense.
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Ovarian cancer is the fifth most common cancer in women,
accounting for nearly 15280 deaths annually in the United States
(Jemal et al, 2007). Standard treatment for ovarian carcinoma
consists of surgery and adjuvant chemotherapy, to which B80% of
patients will obtain a complete response (Fader and Rose, 2007; Gu
et al, 2009). However, relapse rates are nearly 70% and the
majority of patients eventually succumb to disease progression
within 18–24 months (Gadducci et al, 1998, 2005; Berek et al, 1999;
Fehm et al, 2005).
Primary peritoneal cancer (PPC) and ovarian cancer have
similar phenotypic and histological characteristics (Eltabbakh
et al, 1998). Nonetheless, as PPC has an undefined site of
origin and the method of lymphatic dissemination is different
from ovarian cancer, the disease may be a distinct, clinical
entity. Moreover, studies have reported that PPC augurs a
worse prognosis than ovarian cancer, particularly with regard
to progression-free survival and overall survival (Eisenhauer
et al, 2008).
The rationale for intensive surveillance of both ovarian and PPC
is based on the premise that prompt detection and treatment of an
asymptomatic patient will result in improved survival outcomes.
Consequently, to detect recurrent cancer earlier and potentially
improve upon patient prognosis, studies have attempted to
evaluate follow-up protocol at the conclusion of primary treatment
(Vaidya and Curtin, 2003; von Georgi et al, 2004).
Currently, there are only a limited number of formal, recognised
guidelines for the surveillance of ovarian and PPC, particularly for
previously treated patients who are without evidence of disease
(U.S. Preventive Services Task Force, 1996; Vaidya and Curtin,
2003; von Georgi et al, 2004; Gadducci et al, 2007). The
recommendations derived from the National Cancer Institute
Consensus include evaluation of patient symptomatology, physical
examination and monitoring of CA-125 levels every 3 months for
the first 2 years following diagnosis (NIH, 1994). In patients for
whom intensive screening is indicated, serial CT scans and CA-125
have been an integral component of follow-up and therapeutic
management (Sugiyama et al, 1996; Fehm et al, 2005; Zola et al,
2007; Ferrandina et al, 2009). Conversely, physical examination
and vaginal cytology have only offered limited predictive or
survival benefits (Casey et al, 1996; Fehm et al, 2005).
Given the continued expense of obtaining serial gynaecologic
cancer examinations, multiple serologic evaluations and imaging
studies, one may conjecture that a comprehensive approach is
both financially burdensome and anxiety laden for the patient
(Wilson et al, 2004; Lee and Foster, 2009). Despite these concerns,
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sthere have been scant, large population studies addressing the cost
and efficacy of conventional ovarian cancer screening measures
(van Nagell et al, 2007; Havrilesky et al, 2008). In the present
investigation, we documented the number and cost of evaluative
procedures employed by a single gynaecologic oncology service
over a 16-year period in the surveillance of initially diagnosed
ovarian and PPCs. We hypothesise that the CA-125 and imaging
will detect the highest number of recurrent ovarian and PPC cases
in contrast to physical examination and vaginal cytology.
MATERIALS AND METHODS
Patients and eligibility criteria
This retrospective study involved all ovarian and PPC patients
diagnosed and managed at a single, tertiary health care institution
from November 1991 to February 2007. An institutional review
board approved this retrospective study before any patient chart
data were evaluated. Following an assessment of patient records
from our clinical database, the charts of 1495 ovarian cancer
patients were identified and reviewed. Only patients who were
exclusively treated (e.g., underwent cytoreductive surgery and
received all adjuvant therapy) and followed by the individual
group of gynaecologic oncologists were eligible for this study.
Patients who received neoadjuvant chemotherapy were excluded
from the study evaluation.
Surveillance protocol
Surveillance occurred at 3 month intervals for the first 2 years
following diagnosis and completion of primary treatment, at
6-month intervals for the subsequent 3 years, and annually,
thereafter. During each patient evaluation, a CA-125 assay was
obtained and a physical examination was performed. CT scanning
of the abdomen, chest and pelvis was ordered at 6-month intervals
for the first 2 years of follow-up. Additional imaging (e.g., chest
X-ray, pelvic ultrasound, PET scan) was ordered at the discretion
of the physician. Vaginal cytology was obtained at the initial
diagnosis and annually, thereafter.
Physical examination consisted of palpation of the abdomen,
pelvis and lymph-node bearing areas. Abnormal vaginal cytology
resulted in a subsequent colposcopic exam, and if indicated, a
directed biopsy within 2 weeks. In the event of disease progression
on CA-125 (435Uml
 1), a repeat sample was taken within 4
weeks. If the CA-125 results remained positive for disease
progression, but the findings on CT or physical exam were
negative, a confirmatory CT scan and physical exam were
scheduled. If any physical findings were present during the
patient’s exam, but the CA-125 and CT scan were negative, a
follow-up on CA-125 was obtained within 4 weeks and a CT scan
was ordered. If any of the previously described diagnostic
measures identified disease progression 460 days following the
initial detection, the patient data were excluded. We based this
interval on the assumption that within this time frame, a medical
intervention would already have occurred.
Disease recurrence
Recurrent disease was defined as progression in surgically treated
women with no evidence of disease following completion of
primary therapy. If a patient’s symptoms were noted during
physical exam or history, but the CA-125, vaginal cytology and
imaging results were negative, the initial recurrence was classified
in accordance with the physical exam. If the patient exhibited
disease progression on imaging, but had negative physical
findings, a CA-125 within normal limits and normal vaginal
cytology, the initial recurrence was categorised under imaging
findings. If the patient had negative imaging, physical and vaginal
cytology findings, but the CA-125 was indicative of disease
progression, the initial recurrence was classified in accordance
with the CA-125. When a patient presented with any combination
of an elevated CA-125, physical findings or symptoms, abnormal
vaginal cytology or positive imaging result, initial recurrence was
categorised according to the diagnostic measure with the earliest
recorded date.
In addition to the initial recurrence date, confirmatory dates for
all positive diagnostic measures within a predetermined 60 days
clinical time frame were documented for the purpose of
comparative evaluation. Time to recurrence was defined as the
period between initial diagnosis and documentation of disease
recurrence. Recurrences were corroborated via histological,
radiological or cytological evaluation. Once recurrent disease was
established, individual surveillance data were concluded. Following
a diagnosis of recurrent disease, all patients were offered
additional treatment (e.g., surgery, radiation or chemotherapy).
Overall survival was defined as time from the initial diagnosis until
patient expiration, with all causes of death treated equally.
Cost analysis
Cost analysis was based on previously published Southern California
Medicare fee schedules for 2010. The combined (i.e., scan and
radiologist evaluation) reimbursement rate for an abdomino-pelvic/
chest CT scan (with and without contrast) was $1499.00.
The combined reimbursement rate for a chest X-ray was $38.00.
The combined reimbursements for a PET scan and pelvic ultrasound
were $1414.00 and $144.00, respectively. The reimbursement for a
physical examination was $140.00. The reimbursements for vaginal
cytology and CA-125 were $47.00 and $87.00, respectively.
Statistical analysis
All statistical analyses were conducted using MedCalc statistical
software for biomedical research (version 9.5.1 for Windows;
MedCalc Software, Maria Kerke, Belgium). The initial data analysis
was conducted by employing a descriptive statistical approach,
which underwent further examination via ANOVA. Significance
(o0.05) was determined via two-sided P-values. Survival analyses
were conducted via Kaplan–Meier.
RESULTS
From the original group of 1495 patients, 287 satisfied the
established inclusionary criteria and comprised the study popula-
tion. In this group, 240 had epithelial ovarian cancer (EOC), 23 had
PPC and 24 had concurrent ovarian and uterine (COU) cancer. The
median age of the entire study group was 59 years (range; 19–90).
The clinicopathological characteristics for the study participants
are exhibited in Tables 1 and 2.
In the study group, 151 patients developed disease progression.
When examining the different detection modalities, CA-125
(n¼74; 49.0% of cases) and imaging studies (n¼66; 43.7%)
detected the highest number of initial disease recurrence cases.
Physical exam identified 10 (6.6%) cases. Vaginal cytology was the
least effective measure, identifying only one (0.7%) recurrence.
A 60 days clinical interval was established to corroborate
additional diagnoses with the initial abnormal surveillance test
findings. Ultimately, the vast majority of diagnostic verifications
occurred within this established time frame (Figure 1). Imaging
studies confirmed recurrent disease in 45 patients. CA-125
corroborated disease recurrence in 20 patients. Physical exam
and vaginal cytology were each able to confirm only two cases of
recurrent cancer within the predetermined interval.
There were a total of 3569 imaging evaluations ordered over the
16-year study period. This resulted in a cost of $1493459 or 62.7%
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sof the total surveillance cost. During the course of surveillance,
3560 physical exams were administered, resulting in a cost of
$498400. In terms of the CA-125, 4240 lab values were obtained;
this resulted in a cost of $368880. Finally, 457 vaginal cytology
evaluations were obtained at a cost of $21479.
An evaluation of cancer origin (EOC, PPC, COU) and
progression-free interval (PFI) revealed significant differences
(F(2284)¼3.64; P¼0.028). The EOC patients had a more
favourable PFI (34.8 months) than the COU (24.8 months) and
the PPC (22.7 months) patients (Figure 2). Disease stage (I/II-44.3
months vs III/IV-27.4 months) was also predictably associated with
significant PFI differences (F(1,285)¼33.09; Po0.001).
In all, 61 study patients have expired to date. Median OS has not
been reached and current median length of patient follow-up is 42
months (range, 3–228).
DISCUSSION
Several studies have examined the utility of routine surveillance
measures in ovarian cancer follow-up (Vaidya and Curtin, 2003;
von Georgi et al, 2004; Gadducci et al, 2007), yet the issue remains
a challenge for gynaecologic oncologists. Currently, follow-up
procedures include serum CA-125 testing, physical examination,
vaginal cytology and radiological imaging techniques.
In the present investigation, we examined recurrent disease
detection rates for vaginal cytology, physical examination, CA-125
testing and CT imaging during a 16-year period at a single medical
institution. Initially, we presumed that the CA-125 would have
significant prognostic utility as previous reports have documented
Table 2 Pathological characteristics for the uterine component of the
concurrent ovarian and uterine cancer patients (n¼24)
Stage n (%)
IA 15 (62.5)
1B 3 (12.5)
IC 2 (8.3)
II 2 (8.3)
IIIC2 1 (4.2)
IVB 1 (4.2)
Histology
Endometrioid 15 (62.5)
UPSC 4 (16.7)
Clear cell 3 (12.5)
Adenocarcinoma 2 (8.3)
Grade
G1 6 (25.0)
G2 9 (41.7)
G3 8 (33.3)
Lymphovascular space involvement
Yes 5 (20.8)
No 19 (79.2)
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Figure 1 Distribution of confirmatory abnormal studies in the
surveillance of ovary cancer.
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Figure 2 Progression-free survival according to cancer site.
Table 1 Ovarian and primary peritoneal cancer patient clinicopatho-
logical characteristics (n¼287)
Cancer origin n (%)
Epithelial 240 (83.6)
Primary peritoneal 23 (8.0)
Concurrent ovarian and uterine 24 (8.4)
Stage
IA 10 (3.5)
1B 2 (0.7)
IC 10 (3.5)
IIA 4 (1.4)
IIB 20 (7.0)
IIC 16 (5.6)
IIIA 6 (2.1)
IIIB 16 (5.6)
IIIC 181 (62.9)
IV 22 (7.7)
Histology
Adenocarcinoma 22 (7.7)
Papillary serous 168 (58.5)
Endometrioid 55 (19.3)
Clear cell 29 (10.1)
Mucinous 10 (3.5)
Transitional 1 (0.3)
Adenosquamous 1 (0.3)
Psammocarcinoma 1 (0.3)
Grade
G1 29 (10.1)
G2 58 (20.2)
G3 188 (65.5)
Unknown 12 (4.2)
Optimal surgery 255 (88.9)
Suboptimal surgery 32 (11.1)
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sthat increased levels coincided with disease progression in
56–94% of ovarian cancer patients (Rustin et al, 2001; Gadducci
et al, 2004). We also contended that serial imaging would have
high predictive value in detecting recurrent cancer (Funt et al,
2004; Gu et al, 2009).
In reviewing the CA-125 results, our evaluation revealed that
serological evaluation identified the highest number (74 initial
detections and 20 confirmatory diagnoses, 61% of all recurrences)
of disease progression cases. Torizuka et al (2002) reported that
the CA-125 was associated with an accuracy rate of 80% and a
100% positive predictive value in detecting recurrent ovarian
cancer. Garcı ´a-Velloso et al (2007) reported a sensitivity of 57.6%
and a specificity of 93.9% in the follow-up of platinum sensitive
ovarian cancer patients. Conversely, Rustin and van der Burg
(2009), in an EOC population, suggested that surveillance with
serial CA-125 evaluation had limited impact on patient overall
survival. Consequently, the CA-125 cannot be exclusively
employed as a surveillance measure in ovarian cancer because
elevated values may be ascertained in cases of non-malignancy
(Rettenmaier et al, 2005). Further, although normalisation of
CA-125 values may reflect disease regression, this condition is not
assured. Ultimately, our results suggest that given the relatively
low cost per patient recurrence ($3924) in the present investigation
and ease of obtaining this measure, CA-125 evaluation appears
beneficial in the surveillance of ovarian and PPC.
Imaging identified or confirmed 111 (72.1%) instances of
disease recurrence; CT scanning encompassed the vast majority
(77.9%) of radiological techniques within this category. However,
overall imaging was extremely expensive (62.7% of the total
surveillance cost throughout the study period); the cost for this
procedure was $13454 per recurrent cancer diagnosis. Sebastian
et al (2008) retrospectively evaluated the diagnostic utility of CT
scanning in 51 ovarian cancer patients with recurrent disease.
They reported that CT of the chest and abdomen were associated
with an accuracy rate of 89 and 79%, respectively. Conversely,
studies have indicated that CT sensitivity may be compromised in
ovarian cancer surveillance, particularly when there are retro-
peritoneal or lymphatic metastases (Coakley et al, 2002; Murakami
et al, 2006). Despite the relatively high cost of ordering this
diagnostic measure, CT potentially has promise in evaluating
disease severity, thereby providing constructive insight into the
determination of patient management (Funt et al, 2004).
Physical examination bestowed inadequate diagnostic utility in
the current study, detecting only 6.7% of initial recurrences.
Moreover, even when we included both initial and confirmatory
diagnoses (12 cases), the procedure was associated with the highest
cost ($41533) per identified patient recurrence. In the Chan et al
(2008) study, 41 (51%) of recurrent ovarian cancer patients
presented with positive physical findings, of which only 3 were not
corroborated by additional surveillance measures. Menczer et al
(2006) reported similar findings; 78% of their recurrent ovarian
cancer patients were diagnosed during a physical exam, but only
2 out of 43 progressive disease patients had exclusively, positive
physical findings. Our results are in accordance with previous
studies that suggest physical examination has only limited utility
and financial viability in the long-term surveillance of ovarian
cancer. Consequently, one could speculate that as ovarian cancer
patients will continue to undergo a routine physical examination,
the evaluation does not necessarily need to be conducted by a
gynaecologic oncologist.
Vaginal cytology has been included in the intense follow-up of
gynaecologic cancers (Santillan et al, 2008). However, this
procedure has not proven to have sufficient external validity
in effectuating a favourable clinical outcome (Milam et al, 2007).
In the present investigation, vaginal cytology detected the least
number of recurrent cases (one initial detection and two
confirmatory), accounting for 2% of total cases. These results
were similar to the 3.7% rate reported by Milam et al (2007), which
indicated that the risk for ovarian cancer recurrence in the vaginal
apex following hysterectomy was extremely low, even in advanced
stage patients (Patsner et al, 1990; Milam et al, 2007).
In our analysis, the cost of obtaining vaginal cytology was $7159
per recurrent cancer diagnosis. Although this is significantly less
than the $75040 per patient recurrence reported by Bristow et al
(2006) in their endometrial cancer study; our data, nevertheless,
suggest that routine vaginal cytology does not have prognostic
utility nor is it financially justifiable in ovarian cancer surveillance
(Santillan et al, 2008).
Unsurprisingly, PPC patients exhibited the worst PFI (Eisenhauer
et al, 2008). One may conjecture that their unfavourable prognosis
was attributed to more extensive and voluminous disease (Aletti
et al, 2009), although we did not further evaluate this premise.
Conversely, we had suspected that the COU cancer patients might
have exhibited a worse outcome, but essentially, the majority
of the uterine tumours were small volume and low stage. Thus,
the coexistence of two malignancies appeared to adversely
affect patient prognosis only relative to the EOC patients
(24.8 months vs 34.8). We recognise the complications associated
with analysing the patients with concurrent ovarian and endo-
metrial tumours because of the difficulty in determining which
cancer actually recurred. However, as this cancer group comprised
10% of the patient population and clinicians will periodically
encounter them, we contend that their surveillance data are of
significant value.
In our long-term experience following patients with ovarian and
PPCs, we ascertained that serial CA-125 determination and
imaging appear more sensitive in detecting disease progression
than physical examination and vaginal cytology. Therefore, in
attempting to establish a more effective ovarian cancer surveillance
programme, clinicians may consider altering the frequency of
imaging and CA-125 evaluation based upon prognostic risk
factors, such as disease stage and cancer origin, with intent to
diagnose progressive disease earlier and potentially improve
upon patient outcomes (Fehm et al, 2005). We do, however,
recognise that in spite of significant research, ovarian cancer
screening procedures have not proven to reduce patient mortality
(Bast et al, 2007).
We appreciate that there are weaknesses inherent within this
investigation. Study variability may be a concern as the evaluation
was inadequately powered to discern any differences regarding
approaches to surgery, pathological review and recommendations
for adjuvant therapy. An analysis of patient symptomatology and
progressive disease would have potentially benefited the investiga-
tion, but this data are often quite arbitrary and associated with
poor predictive value (Rossing et al, 2010). Selection bias is
another study concern, as the cohort represents a highly select
group of patients who were all treated at a single institution. The
final study results may also have been significantly biased because
of the uneven distribution of the patient groups. In particular, as
PPC patients have a very unfavourable prognosis, they should be
evaluated independently.
We also appreciate that because the patients’ initial recurrence
was categorised according to the diagnostic measure with the
earliest recorded date, the results may have at least partially been
based upon coincidence (i.e., the order in which the procedure was
planned). In the present study, assessing the criteria according to
the clinical scenario potentially confounds the comparative
evaluation of the different surveillance tests.
Ultimately, as more than one surveillance method was clinically
useful in detecting recurrent disease, a predetermined method
(e.g., a biopsy) may have provided more adequate confirmatory
data. This study also did not address the potential for significant
lead-time variability between the recurrences identified via
imaging or biology and the clinical manifestation of progressive
disease. Therefore, we cannot comment specifically on whether the
early detection of disease affects clinical outcome.
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sIn regard to the cost of surveillance measures, we did not take
into account any specific changes in the price of the various
procedures. The study cost assessment would have also benefited
from considering additional variables, such as lost productivity,
travel time, and caregiver expenses related to obtaining these
surveillance tests. Moreover, there is great difficulty in comparing
the cost for procedures over an extended period of time. Finally,
we began the investigation with 1495 patients, but only ended up
with a sample size of 287 patients after applying the study
exclusionary criteria. We may have been too stringent, but at the
inception, the investigators wanted to ensure that all of the patient
demographic, treatment and follow-up data were accessible and
comprehensive. Despite the study limitations, we contend that the
results from this extremely large study of ovarian and PPC patients
are significant. Additional evaluation of routine surveillance in a
larger, more diverse population of ovarian and PPC patients that
incorporates economic costs should be strongly considered.
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